Triducard MB, 35 mg 60 pcs

Indications

Coronary heart disease: prevention of angina attacks (in complex therapy);
Dizziness of vascular origin;
Cochleo-vestibular disorders of ischemic nature (tinnitus, hearing impairment);
Chorioretinal vascular disorders.

Pharmacological effect

Pharmacotherapeutic group:

antihypoxic agent.

ATX code: [С01ЭВ15]

Pharmacological properties

Pharmacodynamics:

Trimetazidine has an antianginal, antihypoxic effect. Directly influencing cardiomyocytes and neurons of the brain, it optimizes their metabolism and function. The cytoprotective effect is due to an increase in energy potential, activation of oxidative decarboxylation and rationalization of oxygen consumption (increased aerobic glycolysis and blockade of fatty acid oxidation).

Supports myocardial contractility, prevents a decrease in the intracellular content of ATP and phosphocreatinine. In conditions of acidosis, it normalizes the functioning of ion channels, prevents the accumulation of calcium and sodium in cardiomyocytes, and normalizes the intracellular content of potassium ions.

Reduces intracellular acidosis and phosphate concentrations caused by myocardial ischemia and reperfusion. Prevents the damaging effects of free radicals, preserves the integrity of cell membranes, prevents activation of neutrophils in the ischemic zone, increases the duration of the electrical potential, reduces the release of creatine phosphokinase from cells and the severity of ischemic damage to the myocardium.

For angina pectoris, it reduces the frequency of attacks (nitrate consumption decreases), after 2 weeks of treatment, exercise tolerance increases, and blood pressure drops decrease. Improves hearing and results of vestibular tests in patients, reduces dizziness and tinnitus. In case of vascular pathology of the eye, it restores the functional activity of the retina.

Pharmacokinetics:

After taking the drug orally, trimetazidine is quickly and almost completely absorbed from the gastrointestinal tract. Bioavailability – 90%.

The time to reach maximum concentration in blood plasma is 2 hours. The maximum concentration after a single dose of 35 mg of trimetazidine is about 55 ng/ml. Easily passes through histohematic barriers. The half-life (T1/2) is 4.5-5 hours. Communication with plasma proteins – 16%. It is excreted from the body by the kidneys (about 60% unchanged).

Special instructions

The drug is not intended to relieve angina attacks!

If an attack of angina occurs, treatment (drug therapy or revascularization) should be reviewed and adapted.

The use of the drug does not affect the ability to drive a car or perform work that requires a high speed of mental and physical reactions.

Active ingredient

Trimetazidine

Composition

One modified-release film-coated tablet contains the active substance trimetazidine dihydrochloride 35 mg.

Pregnancy

The drug Triducard is contraindicated for use during pregnancy and breastfeeding.

Contraindications

Hypersensitivity to any component of Triducard;
Severe liver dysfunction;
Renal failure (creatinine clearance below 15 ml/min);
Pregnancy;
Breastfeeding period;
Age up to 18 years (efficacy and safety have not been established).

Side Effects

Allergic reactions: skin itching.

From the digestive system: rarely – gastralgia, nausea, vomiting.

From the cardiovascular system: rarely – headache, feeling of palpitations.

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 25 °C

Shelf life

3 years.

Manufacturer

North Star NAO, Russia